BCLI News and Press, Brainstorm Cell Therapeutics Inc. From 11/20/23

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal ri...

BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn® in ALS PR Newswire Meeting will take place on December 6 ; Company plans to seek Special Protocol Assessment (SPA) NEW YORK , Nov....

BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia PR Newswire Presentation on NurOwn Phase 3 data demonstrating evidence of biological effect in ALS; Biomarker data reinforce clinical outcomes NEW YORK , Nov. 17, 2023 /PRNewswire...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal ri...

2023-11-14 12:20:09 ET Start Time: 08:30 End Time: 08:58 BrainStorm Cell Therapeutics Inc. (BCLI) Q3 2023 Earnings Conference Call November 14, 2023, 08:30 AM ET Company Participants Chaim Lebovits - President and CEO Stacy Lindborg - Co-CEO Alla Patlis -...

2023-11-14 07:07:42 ET More on BrainStorm Cell Therapeutics Brainstorm Cell Therapeutics: I Anticipate A Positive AdCom But There Are Major Risks Brainstorm realigns resources to support NurOwn development Brainstorm to pull marketing application for ALS therapy ...

BrainStorm Cell Therapeutics Announces Third quarter 2023 Financial Results and Provides Corporate Update PR Newswire Conference call and webcast at 8:30 a.m. Eastern Time today NEW YORK , Nov. 14, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics In...

Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...

Brainstorm Cell Therapeutics Inc. (BCLI) is expected to report $-0.14 for Q3 2023

2023-11-13 12:54:20 ET More on BrainStorm Cell Therapeutics Brainstorm Cell Therapeutics: I Anticipate A Positive AdCom But There Are Major Risks Brainstorm realigns resources to support NurOwn development Brainstorm to pull marketing application for ALS therapy ...